Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation

Regulators granted Lu-PSMA-617 breakthrough therapy designation Wednesday, Novartvis announced, roughly three months after the candidate read out positive Phase III results in metastatic castration-resistant prostate cancer. The move marks not only a win for Novartis but for the up-and-coming radiopharmaceuticals field, which has attracted heavy interest in the last couple years.